Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
15
12
2021
accepted:
14
02
2022
revised:
07
02
2022
pubmed:
12
3
2022
medline:
1
9
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
The category of "oncocytic renal tumors'' includes well-recognized entities, such as renal oncocytoma (RO) and eosinophilic variant of chromophobe renal cell carcinoma (eo-ChRCC), as well as a group of "gray zone" oncocytic tumors, with overlapping features between RO and eo-ChRCC that create ongoing diagnostic and classification problems. These types of renal tumors were designated in the past as "hybrid oncocytoma-chromophobe tumors". In a recent update, the Genitourinary Pathology Society (GUPS) proposed the term "oncocytic renal neoplasm of low malignant potential, not further classified", for such solitary and sporadic, somewhat heterogeneous, but relatively indolent tumors, with equivocal RO/eo-ChRCC features. GUPS also proposed that the term "hybrid oncocytic tumor" be reserved for tumors found in a hereditary setting, typically arising as bilateral and multifocal ones (as in Birt-Hogg-Dubé syndrome). More recent developments in the "gray zone" of oncocytic renal tumors revealed that potentially distinct entities may have been "hidden" in this group. Recent studies distinguished two new entities: "Eosinophilic Vacuolated Tumor" (EVT) and "Low-grade Oncocytic Tumor" (LOT). The rapidly accumulated evidence on EVT and LOT has validated the initial findings and has expanded the knowledge on these entities. Both are uniformly benign and are typically found in a sporadic setting, but rarely can be found in patients with tuberous sclerosis complex. Both have readily distinguishable morphologic and immunohistochemical features that separate them from similar renal tumors, without a need for detailed molecular studies. These tumors very frequently harbor TSC/MTOR mutations that are however neither specific nor restricted to these two entities. In this review, we outline a proposal for a working framework on how to classify such low-grade oncocytic renal tumors. We believe that such framework will facilitate their handling in practice and will stimulate further discussions and studies to fully elucidate their spectrum.
Identifiants
pubmed: 35273336
doi: 10.1038/s41379-022-01057-z
pii: S0893-3952(22)00268-X
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140-1150Informations de copyright
© 2022. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
Perrino, C. M. et al. Morphological spectrum of renal cell carcinoma, unclassified: An analysis of 136 cases. Histopathology 72, 305–319 (2018).
pubmed: 28833389
doi: 10.1111/his.13362
Chen, Y. B. et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat. Commun. 7, 13131 (2016).
pubmed: 27713405
pmcid: 5059781
doi: 10.1038/ncomms13131
Andeen, N. K. et al. Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas. Arch. Pathol. Lab. Med. 143, 494–504 (2019).
pubmed: 30383394
doi: 10.5858/arpa.2018-0104-OA
Trpkov, K. et al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod. Pathol. 34, 1392–1424 (2021).
pubmed: 33664427
doi: 10.1038/s41379-021-00779-w
Trpkov, K. & Hes, O. New and emerging renal entities: A perspective post-WHO 2016 classification. Histopathology 74, 31–59 (2019).
pubmed: 30565301
doi: 10.1111/his.13727
Williamson, S. R. et al. Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer. Am. J. Surg. Pathol. 44, e47–e65 (2020).
pubmed: 32251007
pmcid: 7289677
doi: 10.1097/PAS.0000000000001476
Trpkov, K. et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod .Pathol. 34, 1392–1424 (2021).
pubmed: 33664427
doi: 10.1038/s41379-021-00779-w
Williamson, S. R. et al. Diagnostic criteria for oncocytic renal neoplasms: A survey of urologic pathologists. Hum. Pathol. 63, 149–156 (2017).
pubmed: 28315424
doi: 10.1016/j.humpath.2017.03.004
Hes, O. et al. Oncocytoma. In WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4. (eds. Moch, H. et al.) 43–44 (Lyon, IARC, 2016).
Paner, G. et al. Chromophobe renal cell carcinoma. WHO Classification of Tumours of the Urinary System and Male Genital Organs. (eds Moch, H. et al.) 27–28 (Lyon, IARC, 2016).
Ng, K. L. et al. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): Can novel molecular biomarkers help solve an old problem? J. Clin. Pathol. 67, 97–104 (2014).
pubmed: 24170213
doi: 10.1136/jclinpath-2013-201895
Ng, K. L. et al. A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma. J. Clin. Pathol. 69, 661–671 (2016).
pubmed: 26951082
doi: 10.1136/jclinpath-2015-203585
Skala, S. L. et al. Next-generation RNA sequencing-based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur. Urol. 78, 63–74 (2020).
pubmed: 32299640
pmcid: 8996310
doi: 10.1016/j.eururo.2020.03.003
McGillivray, P. D. et al. Distinguishing benign renal tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur. Urol. 79, 107–111 (2021).
pubmed: 32972793
doi: 10.1016/j.eururo.2020.09.017
Mai, K. T., Dhamanaskar, P., Belanger, E. & Stinson, W. A. Hybrid chromophobe renal cell neoplasm. Pathol. Res. Pract. 201, 385–389 (2005).
pubmed: 16047948
doi: 10.1016/j.prp.2005.03.008
Petersson, F. et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: A clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch. 456, 355–365 (2010).
pubmed: 20300772
doi: 10.1007/s00428-010-0898-4
Hes, O., Petersson, F., Kuroda, N., Hora, M. & Michal, M. Renal hybrid oncocytic/chromophobe tumors—a review. Histol. Histopathol. 28, 1257–1264 (2013).
pubmed: 23740406
Pavlovich, C. P. et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am. J. Surg. Pathol. 26, 1542–1552 (2002).
pubmed: 12459621
doi: 10.1097/00000478-200212000-00002
Gobbo, S. et al. Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical, and cytogenetic profiles. Am. J. Surg. Pathol. 34, 620–626 (2010).
pubmed: 20305535
doi: 10.1097/PAS.0b013e3181d73293
Srigley, J. R. et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am. J. Surg. Pathol. 37, 1469–1489 (2013).
pubmed: 24025519
doi: 10.1097/PAS.0b013e318299f2d1
Moch, H., Humphrey, P. A., Ulbright, T. M. & Reuter, V. E., eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. (Lyon, IARC, 2016).
Trpkov, K. et al. High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. Histopathology 75, 440–442 (2019).
pubmed: 31002177
doi: 10.1111/his.13876
Lerma, L. A., Schade, G. R. & Tretiakova, M. S. Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex. Hum. Pathol. 116, 1–11 (2021).
pubmed: 34153307
doi: 10.1016/j.humpath.2021.06.002
Ruiz-Cordero, R. et al. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod. Pathol. 32, 1698–1707 (2019).
pubmed: 31231128
doi: 10.1038/s41379-019-0304-y
Mohanty, S. K. et al. Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway. Mod. Pathol. 35, 361–375 (2022).
pubmed: 34802045
doi: 10.1038/s41379-021-00969-6
Amin, M. B. et al. Chromophobe renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am. J. Surg. Pathol. 32, 1822–1834 (2008).
pubmed: 18813125
doi: 10.1097/PAS.0b013e3181831e68
Przybycin, C. G. et al. Chromophobe renal cell carcinoma: A clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am. J. Surg. Pathol. 35, 962–970 (2011).
pubmed: 21602658
doi: 10.1097/PAS.0b013e31821a455d
Hakimi, A. A. et al. TCEB1-mutated renal cell carcinoma: A distinct genomic and morphological subtype. Mod. Pathol. 28, 845–853 (2015).
pubmed: 25676555
pmcid: 4449825
doi: 10.1038/modpathol.2015.6
Shah, R. B. et al. “Renal Cell Carcinoma With Leiomyomatous Stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am. J. Surg. Pathol. 44, 571–581 (2020).
pubmed: 31850909
doi: 10.1097/PAS.0000000000001422
Stewart-Merrill, S. B. et al. Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J. Clin. Oncol. 33, 4151–4157 (2015).
pubmed: 26351352
doi: 10.1200/JCO.2015.61.8009
Ohashi, R. et al. Loss of CDKN1A mRNA and protein expression are independent predictors of poor outcome in chromophobe renal cell carcinoma patients. Cancers 12, 465 (2020).
pmcid: 7072616
doi: 10.3390/cancers12020465
Alaghehbandan, R. et al. Comprehensive review of numerical chromosomal aberrations in chromophobe renal cell carcinoma including its variant morphologies. Adv Anat Pathol 28, 8–20 (2021).
pubmed: 33021507
doi: 10.1097/PAP.0000000000000286
Thoenes, W. et al. Chromophobe cell renal carcinoma and its variants—a report on 32 cases. J Pathol 155, 277–287 (1988).
pubmed: 2459332
doi: 10.1002/path.1711550402
He, H. et al. “High-grade oncocytic renal tumor”: Morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchow Arch. 473, 725–738 (2018).
doi: 10.1007/s00428-018-2456-4
Chen, Y. B. et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am. J. Surg. Pathol. 43, 121–131 (2019).
pubmed: 30303819
pmcid: 6686675
doi: 10.1097/PAS.0000000000001170
Kapur, P. et al. Eosinophilic vacuolated tumor of the kidney: A review of evolving concepts in this novel subtype with additional insights from a case with MTOR mutation and concomitant chromosome 1 loss. Adv. Anat. Pathol. 28, 251–257 (2021).
pubmed: 34009776
pmcid: 8205969
doi: 10.1097/PAP.0000000000000299
Gupta, S. et al. Renal Neoplasia in Tuberous Sclerosis: A study of 41 patients. Mayo Clin. Proc. 96, 1470–1489 (2021).
pubmed: 33526281
doi: 10.1016/j.mayocp.2020.11.004
Trpkov, K. et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): A distinct entity? Histopathology 75, 174–184 (2019).
pubmed: 30895640
doi: 10.1111/his.13865
Kravtsov, O. et al. Low grade oncocytic tumor of kidney (CK7-positive, CD117-negative). A single institution experience with incidence and clinicopathologic characteristics. Hum. Pathol. (2021). Online ahead of print.
Guo, Q. et al. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: The new evidence from China. Virchows Arch. 478, 449–458 (2021).
pubmed: 32918598
doi: 10.1007/s00428-020-02927-0
Akgul, M., Al-Obaidy, K. I., Cheng, L. & Idrees, M. T. Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: A review of 23 cases from a single tertiary institute. J. Clin. Pathol. (2021). Online ahead of print.
Kapur, P. et al. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Mod. Pathol. 35, 333–343 (2022).
pubmed: 34538873
doi: 10.1038/s41379-021-00896-6
Ishikawa, N. et al. A case of low-grade oncocytic tumor/chromophobe renal cell carcinoma (oncocytic variant) of the kidney. Case Rep. Pathol. 2021, 6684777 (2021).
pubmed: 33680526
pmcid: 7906815
Sharma, D., Pai, T., Prakash, G., Desai, S. & Menon, S. Low-grade oncocytic tumor: Report of two cases of an emerging entity in the spectrum of oncocytic renal neoplasms. Turk. Pathol. Derg. (2021). Online ahead of print.
Mansoor, M., Siadat, F. & Trpkov, K. Low-grade oncocytic tumor (LOT) – a new renal entity ready for a prime time: An updated review. Histol. Histopathol. https://doi.org/10.14670/HH-18-435 . (2022). Online ahead of print.
Morini, A. et al. Low-grade oncocytic renal tumor (LOT): Mutations in mTOR pathway genes and low expression of FOXI1. Mod. Pathol. 35, 352–360 (2022).
pubmed: 34531523
doi: 10.1038/s41379-021-00906-7
Farcas, M. et al. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: Next-generation sequencing multi-institutional study of 19 cases. Mod Pathol. 35, 344–351 (2022). (2021).
pubmed: 34521993
doi: 10.1038/s41379-021-00923-6
Siadat, F. & Trpkov, K. ESC, ALK, HOT and LOT: Three letter acronyms of emerging renal entities knocking on the door of the who classification. Cancers 12, 168 (2021).
doi: 10.3390/cancers12010168
Miettinen, M. et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 38, 13–22 (2014).
pubmed: 24145643
pmcid: 3991431
doi: 10.1097/PAS.0b013e3182a0218f
Tong, K. & Hu, Z. FOXI1 expression in chromophobe renal cell carcinoma and renal oncocytoma: A study of The Cancer Genome Atlas transcriptome-based outlier mining and immunohistochemistry. Virchows Arch. 478, 647–658 (2021).
pubmed: 32812119
doi: 10.1007/s00428-020-02900-x
Guo, J. et al. Tuberous sclerosis-associated renal cell carcinoma: A clinicopathologic study of 57 separate carcinomas in 18 patients. Am. J. Surg. Pathol. 38, 1457–1467 (2014).
pubmed: 25093518
doi: 10.1097/PAS.0000000000000248
Schultz, L. et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am. J. Surg. Pathol. 35, 1549–1556 (2011).
pubmed: 21881486
pmcid: 3505672
doi: 10.1097/PAS.0b013e31822895e5
Roldan-Romero, J. M. et al. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. Mod. Pathol. 33, 2580–2590 (2020).
pubmed: 32616874
doi: 10.1038/s41379-020-0607-z
Shah, A. et al. Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) harbor recurrent mutations in KMT2C and TSC2 Genes. Am. J. Surg. Pathol. 44, 1479–1486 (2020).
pubmed: 32604168
doi: 10.1097/PAS.0000000000001530
Chaux, A. et al. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. Hum. Pathol. 44, 2323–2330 (2013).
pubmed: 23953228
doi: 10.1016/j.humpath.2013.05.014
Kwiatkowski, D. J. et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 22, 2445–2452 (2016).
pubmed: 26831717
pmcid: 4976069
doi: 10.1158/1078-0432.CCR-15-2631